FDA Approves Retifanlimab-dlwr with Carboplatin and Paclitaxel and as a Single Agent for Squamous Cell Carcinoma of the Anal Canal By Ogkologos - June 20, 2025 867 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the POD1UM-303/InterAACT 2 and POD1UM-202 studies Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR Experts Urge to Remove Care Inequalities for Adolescents and Young Adults... April 8, 2021 When Natural Disasters Strike, This Program Helps Provide Relief To People... October 3, 2019 Stereotactic Radiosurgery Not Superior in Terms of Pain Response Compared with... April 26, 2023 Bride Cancels Engagement Photos To Share Special Dance With Terminal Dad. April 19, 2019 Load more HOT NEWS Our new strategy to make discoveries, drive progress, and bring hope Omission of Completion Axillary Lymph Node Dissection Noninferior to More Extensive... EMA Recommends Granting a Conditional Marketing Authorisation for Obecabtagene Autoleucel How the history of medicine influenced our perception of cancer
